The symptoms of Parkinson's disease are treated primarily by dopamine replacement therapy such as levodopa or dopamine agonists. Long-term therapy with levodopa is associated with motor complications such as the development of a shortening response to each dose, which is called the "wearing-off phenomenon," as well as involuntary movements.
Istradefylline completed its clinical trials. Phase II and III clinical studies were conducted with Istradefylline in Parkinson's disease patients experiencing "wearing-off phenomenon" while taking levodopa alone, or while taking levodopa with other Parkinson's disease medications. Based on the clinical efficacy and safety data obtained, the company submitted an NDA for Istradefylline as adjunctive therapy to levodopa/carbidopa for the treatment of idiopathic Parkinson's disease to improve motor function in patients who experience motor response complications.
Now the wait begins. The approval could come within months, or the process could drag on for two years or more. Still we're pleased there could "soon" be one more tool for treating Parkinson's disease symptoms. We just wish we could report on cures!
Our treatment options category is a great place to learn more about Parkinson's treatments.
